MedTrace Logo

A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)

NCT03815279 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-08-16

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.

Conditions

Interventions

DRUG

Carfilzomib

Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24

DRUG

Lenalidomide

Lenalidomide PO once daily on days 1-21 of a 28 day cycle

DRUG

Dexamethasone

Dexamethasone will be administered weekly

Sponsors & Collaborators

Principal Investigators

  • Sigurdur Y Kristinsson, MD, PhD · Landspitali University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2024-01-31
Completion
2028-01-31

Countries

  • Iceland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03815279 on ClinicalTrials.gov